title: GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol.
abstract: Serum albumin, cholinesterase, and cholesterol were measured in ten patients with aplastic anemia and eight with myelodysplastic syndrome who received the administration of recombinant human GM-CSF. Serum albumin, cholinesterase, and cholesterol were significantly lowered by the administration of GM-CSF and recovered after the cessation of GM-CSF. These data suggest that GM-CSF impairs the biosynthesis of liver cells and that cholesterol-lowering activity of GM-CSF, which is previously reported, is due to the impairment of liver biosynthesis by GM-CSF.
authors.affiliation: First Department of Internal Medicine, Niigata University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Nikkuni
authors.forename: Y
authors.initials: Y
authors.lastname: Moriyama
authors.forename: A
authors.initials: A
authors.lastname: Shibata
mesh_terms: D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy; D002784:Cholesterol / Q000097:blood*; D002802:Cholinesterases / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012709:Serum Albumin / Q000032:analysis*
chemical_list: D011994:Recombinant Proteins; D012709:Serum Albumin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D002784:Cholesterol; D002802:Cholinesterases